Literature DB >> 17490730

Von Willebrand disease - phenotype versus genotype: deficiency versus disease.

David Lillicrap1.   

Abstract

Von Willebrand disease (VWD) is classified into three primary subtypes; type 1 includes partial quantitative deficiency, type 2 (A, B, M and N) includes qualitative defects and type 3 includes virtually complete deficiency of von Willebrand factor (VWF). Type 2A includes variants with decreased platelet adhesion caused by selective deficiency of high molecular weight VWF multimers. Type 2B includes variants with increased affinity for platelet glycoprotein Ib. Type 2M includes variants with markedly defective platelet adhesion despite normal sized VWF multimers. Finally, type 2N includes variants with markedly decreased affinity for factor VIII (FVIII). Studies have begun to address the association between particular genetic variants of VWF and the disease phenotype. For example, the recessive type 3 disease appears to be due to a variety of mutations that result in a null phenotype, while type 2N disease results from a group of recessive missense mutations that interfere with FVIII binding. Recently, the molecular pathogenesis of type 1 VWD has begun to be characterised revealing a diverse spectrum of genetic changes. In two large studies, patients with type 1 VWD were found to be heterozygous for a variety of missense, splice site and transcriptional mutations. In some patients, more than one variant sequence was present, and in a significant number of individuals no changes were evident in the VWF gene. These results suggest that the molecular correlates for type 1 VWD are complex and, in addition to a wide array of changes at the VWF locus, are likely to involve mutations in other genes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17490730     DOI: 10.1016/j.thromres.2007.03.014

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow.

Authors:  Judith M E M Cosemans; Saskia E M Schols; Lucia Stefanini; Susanne de Witt; Marion A H Feijge; Karly Hamulyák; Hans Deckmyn; Wolfgang Bergmeier; Johan W M Heemskerk
Journal:  Blood       Date:  2010-10-29       Impact factor: 22.113

Review 2.  The molecular genetics of von Willebrand disease.

Authors:  Ergül Berber
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831

Review 3.  Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.

Authors:  Marcus Stockschlaeder; Reinhard Schneppenheim; Ulrich Budde
Journal:  Blood Coagul Fibrinolysis       Date:  2014-04       Impact factor: 1.276

4.  The Cost of Von Willebrand Disease in Europe: The CVESS Study.

Authors:  George Morgan; Sarah Brighton; Mike Laffan; Jenny Goudemand; Bethany Franks; Alan Finnegan
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

5.  Antigenic Peptides Capable of Inducing Specific Antibodies for Detection of the Major Alterations Found in Type 2B Von Willebrand Disease.

Authors:  Marina de Oliveira Paro; Cyntia Silva Ferreira; Fernanda Silva Vieira; Marcos Aurélio de Santana; William Castro-Borges; Maria Sueli Silva Namen-Lopes; Sophie Yvette Leclercq; Cibele Velloso-Rodrigues; Milton Hércules Guerra de Andrade
Journal:  Int J Pept       Date:  2013-07-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.